Latest news for Acomplia

[admin]

Rimonabant could Help Block Development of Alcoholic Fatty Liver



Diet drug rimonabant (Acomplia / Zimulti), which has been approved for use in Europe and a number of other countries but not the United States, may be useful in blocking the development of alcoholic fatty liver, according to U.S. researchers.
Reporting in the March issue of the journal Cell Metabolism, the researchers from the National Institute on Alcohol Abuse and Alcoholism found that mice treated with rimonabant, a drug designed to block cannabinoid receptors, become resistant to alcohol's fat-building effects in the liver.
Alcoholic fatty liver can progress to more serious disease, and alcoholism is a leading cause of liver disease in the U.S. and other western societies.

Clinical trials testing the effectiveness of CB1 receptor blockers in the treatment of both alcoholic and nonalcoholic fatty liver and their more severe sequelae may be warranted," the researchers concluded.


Acomplia news - 19th July, 2007


As expected, Sanofi Aventis has changed the labelling on Acomplia for the European Union market, to contraindicate it for patients with ongoing depressive illness, or for patients currently undergoing treatment for depression. This is because of the risk of psychiatric side effects.
These side effects have been known about, and doctors have been warned about them, since June 2006. It is just now that an upgrading of the warning has occurred following advice by the CHMP - the Committee for Medicinal Products for Human Use.


Acomplia news - 21st Aug, 2007
Acomplia has been predicted to become the first of a number of blockbuster Canniboid drugs that will be used for a variety of treatments, according to a report on Piribo.com.
The report states that canniboid drugs such as Acomplia, and others including Marion, Cesamet and Sative will be used to treat a wide variety of conditions, from weight loss to pain relief.